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Objective. To evaluate the eﬀectiveness of astragalus injection (a traditional Chinese patent medicine) for patients with renal
damageinducedbyhypertensionaccordingtotheavailableevidence.Methods.WesearchedMEDLINE,ChinaNationalKnowledge
Infrastructure (CNKI), Chinese VIP Information, China Biology Medicine (CBM), and Chinese Medical Citation Index (CMCI),
and the date of search starts from the ﬁrst of database to August 2011. No language restriction was applied. We included
randomized controlled trials testing astragalus injection against placebo or astragalus injection plus antihypertensive drugs against
antihypertensive drugs. Study selection, data extraction, quality assessment, and data analyses were conducted according to the
Cochranereviewstandards.Results.5randomizedtrials(involving429patients)wereincludedandthemethodologicalqualitywas
evaluated as generally low. The pooled results showed that astragalus injection was more eﬀective in lowering β2-microglobulin
(β2-MG), microalbuminuria (mAlb) compared with placebo, and it was also superior to prostaglandin in lowering blood urea
nitrogen (BUN), creatinine clearance rate (Ccr). There were no adverse eﬀects reported in the trials from astragalus injection.
Conclusions. Astragalus injection showed protective eﬀects in hypertensive renal damage patients, although available studies are
not adequate to draw a deﬁnite conclusion due to low quality of included trials. More rigorous clinical trials with high quality are
w a r r a n t e dt og i v eh i g hl e v e lo fe v i d e n c e .
1.Introduction
Hypertensive renal damage has been deﬁned as being char-
acterized by the changes in renal structure and function
which was caused by hypertension. Renal damage is one of
three hypertensive complications. Hypertension could cause
renal damage in early stage, and the renal damage often
happens insidiously and persists many years without any
typical clinical symptoms. In the past ten years, the incidence
ofend-stagerenaldisease(ESRD)wasrisingatanannualrate
of 9% and 28% was caused by hypertension [1]. In recent
years,theincidenceofESRDcausedbyhypertensionwasalso
increased in China [2].
At present, antihypertensive drugs have been shown to
be eﬀective in lowering blood pressure and thus reducing
morbidity and mortality of cardiovascular diseases. Angiot-
ensin-converting enzyme inhibitors (ACEI) or angiotensin
II receptor blocker (ARB) could also exert kidney protective
eﬀect by dilating eﬀerent arterioles more than aﬀerent
arteriole, decreasing urinary albumin, and inhibiting the
glomerulosclerosis. However, the treatment of hypertensive
renal damage still needs to be further improved even on the
basis of ACEI or ARB. Astragalus injection is a preparation
of an extract of Radix Astragali. The major components are
astragalosides[3],andtheotherpharmacologicalingredients
include polysaccharides, ﬂavones, and aminoacids. Modern
pharmacological research has indicated that astragalus
injection could enhance myocardial contractility, improve
circulation, protect myocardial cells and regulate immune
function [4, 5]. Recent reviews [6–8] further indicated the
potential beneﬁt of astragalus injection in the treatment of
hypertensive renal damage. The following systematic review
aims to test whether astragalus injection is eﬀective and safe
in treating hypertensive renal damage.2 Evidence-Based Complementary and Alternative Medicine
2. Methods
2.1. Database and Search Strategies. We searched MEDLINE,
China National Knowledge Infrastructure (CNKI), Chinese
VIP Information, China Biology Medicine (CBM), and Chi-
nese Medical Citation Index (CMCI). The date of search was
from the ﬁrst of database start to August 2011. No language
restrictions were applied. We used the terms “hypertensive
renal damage”, “hypertensive renal injury”, “astragalus injec-
tion”, and “Huangqi injection”. Various combinations of the
terms were used, depending on the database searched.
2.2. Inclusion Criteria. (1) Randomized controlled trials
(RCT); (2) male or female patients, of any age or ethnic
origin, who had hypertensive renal damage. Hypertensive
renal damage was diagnosed on the basis of: (i) a history
of essential hypertension, (ii) persistent proteinuria, (iii)
hypertensiveretinopathy,(iv)primaryrenaldiseasesorother
secondary renal disease was excluded; (3) the intervention
measure was astragalus injection, astragalus injection plus
placebo, or astragalus injection plus antihypertensive drugs;
(4) all trials had to report clinically relevant outcome mea-
sures of hypertensive renal damage; (5) the treatment should
be at least two weeks. Outcome measures include results
of blood pressure, renal function, clinical comprehensive
eﬀect, and Traditional Chinese medicine (TCM) syndrome
diﬀerentiation. Duplicated publications reporting the same
groups of participants were excluded.
2.3. Data Extraction and Quality Assessment. Two reviewers
(T. Sun, H. Xu) extracted data independently. We assessed
the methodological quality of all included trials by using the
table of risk of bias provided by RevMan 5.1.0. The scale
consists of seven items pertaining to description of random
sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessment,
incompleteoutcomedata,selectivereporting,andotherbias.
2.4. Data Synthesis. We used RevMan 5.1.0 provided by
Cochrane Collaboration to analyse the data. Dichotomous
data were expressed as relative risk (RR) and continuous
outcomes as weighted mean diﬀerence (WMD), both with
95% conﬁdence intervals (CI). Heterogeneity was assessed
using the I2 test with the signiﬁcance level set at I2 over 50%
or P<0.1. In the absence of signiﬁcant heterogeneity, we
pooled data using a ﬁxed-eﬀect model (I2 < 50%), otherwise
we using random eﬀects model (I2 > 50%) [9].
3. Results
3.1. Description of Included Trials. Our search identiﬁed 32
references. We excluded 27 of these articles. Flow diagram of
the article selection for this study is shown in Figure 1.
The search yielded 5 eligible trials, which were all con-
ducted and published in China. A total of 429 participants
with renal damage induced by hypertension were included in
the 5 trials. The proportion of male participants was 66.8%.
All the trials included inpatients, and the average size of the
trials was 86 patients (ranging from 48 to 127 participants).
Five trials enrolled patients with renal damage induced with
hypertension. The diagnostic criteria of trials were based on
the guidelines for prevention and treatment of hypertension
in China [4, 5], clinical manifestations, and laboratory tests
[3, 6, 7]. Three trials were astragalus injection combined
with antihypertensive drugs against antihypertensive drugs,
one trial was astragalus injection against placebo, and one
trial was astragalus injection against prostaglandin. No trial
reported outcomes of the incidence of complications, health
economic costs, quality of life, or adverse eﬀects. The
outcomes that were reported included twenty-four hours
urinary protein content, microalbuminuria (mAlb), β2-mi-
croglobulin (β2- M G ) ,b l o o du r e an i t r o g e n( B U N ) ,s e r u m
creatinine (Scr), and creatinine clearance rate (Ccr). Char-
acteristics of included studies were shown in Table 1.
3.2. Methodological Quality of Included Trials. The method-
ological quality of all the ﬁve trials was very low (Figure 2):
none of trials reported sample calculation, the sample size of
trialswassmall.Thesetrialsprovidedlimitedinformationon
allocation concealment and blinding, and they were all lack
of description of the allocation sequence generation. All the
trials did not mention followup. We contacted the author for
further information but regrettably no information has been
provided to date.
3.3. Eﬀect of Interventions. Three trials [3, 5, 7]g a v eb i o -
chemical indices to analyse the eﬀective of astragalus injec-
tion. One trial [4] only gave the number of patients who had
symptomatic improvement, and one trial [6]g a v eb o t hb i o -
chemical indices and the number of patients who had symp-
tomatic improvement. All were showed in Tables 2 and 3.
3.3.1. The Analysis of Improvement of Renal Damage Indices.
It was not possible to pool the data on renal damage indi-
cators, since the results describing varied indicators to prove
the curative eﬀect of astragalus injection.
In the Ji trial [10], the experimental group used astra-
galus injection (n = 54), while glucose injection was admin-
istered in the control group. Astragalus injection showed
signiﬁcant eﬀect on indicators of β2-MG (MD −15.14,
95%CI −21.61 to −8.67) and mAlb (MD −28.41, 95%CI
47.67 to −9.15).
Xu trial [11] used astragalus injection combined with
Telmisartan and Plendil in the experimental group (n =
26), while Telmisartan and Plendil were administered in the
control group. Only indicators of pulse pressure (MD −7.00,
95%CI −11.56 to −2.44), systolic blood pressure (SBP) (MD
−21.70, 95%CI −31.24, −12.16), and twenty-four hours
urinary protein content (MD −0.05, 95%CI −0.07, −0.04)
showed signiﬁcant diﬀerences.
In He trial [12], the experimental group used astragalus
injection (n = 50), and prostaglandin was used in the
control group. Astragalus injection showed signiﬁcant eﬀect
on indicator of BUN (MD −7.39, 95%CI −9.83, −4.95) and
Ccr (MD 6.84, 95%CI 4.57, 9.11).Evidence-Based Complementary and Alternative Medicine 3
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CNKI VIP CBM CMCI MEDLINE
Total
Reading title and abstracts, we
excluded 25 of duplication, non-
clinical studies, or had study
objective diﬀerent from this
review.
Included
Non-RCT
RCT
(n =32)
(n =7)
(n =2)
(n =5)
Figure 1: Flow diagram of the article selection for this study.
Table 2: The Analysis of Improvement of renal damage indices.
Renal damage indices and comparison between the groups No. of studies WMD [95% CI] P value
β 2-MG
Astragalus versus glucose injection [10]1 −15.14 [−21.61, −8.67] P<0.00001
mAlb
Astragalus versus glucose injection [10]1 −28.4 [−47.67, −9.15] P = 0.004
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]1 −4.20 [−7.47, −0.93] P = 0.01
eGFR
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11] 1 4.10 [−2.38, 10.58] P = 0.21
pulse pressure
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]1 −7.00 [−11.56, −2.44] P = 0.003
SBP
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]1 −21.70 [−31.24, −12.16] P<0.00001
DBP
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]1 −4.20 [−11.02, 2.62] P = 0.23
serum potassium
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]1 −0.08[−0.28, 0.12] P = 0.44
twenty-four hours urinary protein content
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]1 −0.05 [−0.07, −0.04] P<0.00001
Astragalus plus Lotensin, Plendil versus Lotensin, and Plendil [13]1 −0.21 [−0.50, 0.08] P = 0.15
BUN
Astragalus versus prostaglandin [12]1 −7.39 [−9.83, −4.95] P<0.00001
Scr
Astragalus versus prostaglandin [12]1 −3.37 [46.05, 39.31] P = 0.88
Ccr
Astragalus versus prostaglandin [12] 1 6.84 [4.57, 9.11] P<0.00001Evidence-Based Complementary and Alternative Medicine 5
Table 3: The analysis of comprehensive therapeutic eﬀect.
Symptom and sign No. of studies Intervention (n/N) Control (n/N) RR [95%CI] P value
Astragalus plus thiazine diuretics versus thiazine diuretics 1 10/64 32/64 0.18 [0.08, 0.41] P<0.00001
Astragalus versus prostaglandin 1 2/50 13/46 0.11 [0.02, 0.50] P = 0.005
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Figure 2: Risk of bias summary.
In Yao trial [13], there was no signiﬁcant diﬀerence be-
tween astragalus injection plus Lotensin and Plendil group
and Lotensin and Plendil group, according to indicator of
twenty-four hours urinary protein content.
3.3.2. Symptoms and Signs. There were only two trials who
reported the improvement on symptoms and signs (Table 3).
However, they were all for comprehensive therapeutic eﬀect.
We cannot obtain the number of patients with individual
symptoms and the data of individual symptoms improve-
ment after treatment. So we cannot get the analysis of com-
parison between groups.
3.4. Final Indicator at Endpoint. None of the trial reported
the mortality rate or the incidence of complication.
3.5. Sensitivity Analysis, Subgroup Analysis, and Publication
Bias. The number of trials was too small to conduct any suf-
ﬁcient additional analysis of sensitivity, subgroup, and pub-
lication bias.
3.6. Adverse Reaction. None of the trial reported the obser-
vation of side eﬀects.
4. Discussion
Our systematic review suggested that astragalus injection
may be eﬀective on laboratory indices of renal damage (β2-
M G ,m A l b ,p u l s ep r e s s u r e ,S B P ,B U N ,C c r )o ri m p r o v e m e n t
of symptoms and signs. However, according to potential
publication bias and low-quality trials, available data are not
adequateto draw adeﬁniteconclusion ofastragalusinjection
in treating renal damage induced by hypertension. More
speciﬁcally, the positive ﬁndings should be interpreted
conservatively due to the following facts.
The ﬁve trials included in this paper had risk of bias in
terms of design, reporting, and methodology. They provided
only limited descriptions of study design, allocation conceal-
ment, and baseline data. All the ﬁve RCTs prohibited us from
performing meaningful sensitivity analysis. The included
trials were heterogeneous in the populations (adults, elderly
people) and the reported outcomes. All the included trials
were not multicenter, large scale RCTs.
The primary goal of treatment for renal damage induced
by hypertension is to prevent death or progression to
complications. The outcomes from all the included trials
are mainly laboratory indices and symptom improvement.
There is a lack of data from all the trials on clinically relevant
outcomes such as the mortality, incidence of complications,
and quality of life.
Nevertheless, astragalus injection is administered for
treating renal damage induced by hypertension in China.
We have identiﬁed more than 30 randomized trials on this
topic until now. However, most of them are not eligible
for the review due to inadequate design, conducting, and
reporting of the trials. Chinese researchers must be aware of
the need to design and use appropriate statistical methods in
future RCTs of astragalus injection and to measure clinical
outcomes rather than physiological (surrogate) outcomes.
All the ﬁve trials did not report that adverse events. A
conclusion about the safety of astragalus injection cannot
be made. In China, it is widely believed that it is safe to
use herbal medicines for various conditions. All the trials
did not report that adverse events may reﬂect current situ-
ation. However, the safety of herbal medicines needs to be
monitored carefully and reported appropriately in the future
clinical trials. In fact, we found that some reports [14–16]
indicated that astragalus injection had adverse outcomes.
Althoughweconductedcomprehensivesearches,weonly
identiﬁed and included trials published in Chinese. Most of
the trials are small sample with positive ﬁndings. We tried to6 Evidence-Based Complementary and Alternative Medicine
avoid language bias and location bias, but we cannot exclude
potential publication bias. We have conducted extensive
searches for unpublished material, but at the same time we
cannot neglect the fact that trials with negative ﬁndings
remain unpublished.
Based on this systematic review, the eﬀectiveness and
safety of astragalus injection in patients with hypertensive
renal damage is uncertain. The evidence is inconclusive due
to poorly designed and low-quality trials. There is a need for
additionalRCTsthatemphasizenotonlygoodclinicaldesign
but also more elaborated description of the intervention
and clinically relevant outcomes including the mortality, in-
cidence of complications, and quality of life.
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